A Phase 3 interventional study of Leflunomide and Methotrexate in Rheumatoid Arthritis, sponsored by Genentech, Inc.. Terminated at 266 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-12.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Hoffmann-La Roche.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 11th largest by enrollment of the 141 interventional ones that give a count, is one of 15 that started in 2007, is one of 85 in phase 3, and was the 33rd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Brazil, Poland
Ages 18+
Hoffmann-La Roche · Sites in United States, Argentina, Belgium and 9 more countries
Ages 18+
By country, each count listing its studies:
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
219 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 22 · Phase 3 85 · Phase 4 28
First in 2001; this study’s year is marked. 15 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 836 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 132 across the 141 interventional studies, 182 across the 78 observational. Of the 214 that completed or were terminated, 139 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
1 of the studies in Arthritis, Rheumatoid by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07137598Hoffmann-La RocheA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | 2027-04-17 |
Add it to your calendar (.ics) → With an account.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-alpha therapy. Patients will be randomized to receive placebo, 200mg of intravenous ocrelizumab, or 500mg of i.v. ocrelizumab on days 1 and 15. A repeat course of i.v. treatment will be administered at weeks 24 and 26. All patients will receive stable doses of either concomitant methotrexate (7.5-25mg/week) or leflunomide (10-20mg po daily) and may receive additional DMARDs. The treatment period is planned for 48 weeks (until primary analysis) and then participants will enter the open label phase until the drug is commercialized. Target sample size is 1000.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 2 intravenous (IV) infusions of 200 milligram (mg) of ocrelizumab, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
Drug: Leflunomide · Drug: Methotrexate · Drug: Ocrelizumab
Participants will receive 2 IV infusions of 500 mg of ocrelizumab, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
Drug: Leflunomide · Drug: Methotrexate · Drug: Ocrelizumab
Participants will receive ocrelizumab matching placebo IV in two infusions, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
Drug: Leflunomide · Drug: Methotrexate · Drug: Placebo
Oral repeating dose
Oral or parenteral repeating dose
Intravenous repeating dose (200mg)
Intravenous repeating dose (500mg)
Intravenous repeating dose
Percentage of Participants With American College of Rheumatology 20 (ACR20) Responses
ACR20 response: greater than or equal to (≥) 20% improvement in tender or swollen joint counts and 20% improvement in 3 of the following 5 criteria: 1) Physician's global assessment of disease activity, 2) participant assessment of disease activity, 3) Patient Assessment of Pain (visual analog scale \[VAS\]), 4) participant assessment of functional disability via a Health Assessment Questionnaire (HAQ), and 5) erythrocyte sedimentation rate (ESR) at each visit.
Time frame: Weeks 24 and 48
Percentage of Participants With a Major Clinical Response
Major clinical response was defined as achieving an ACR70 response and maintaining this response for a consecutive period of at least 6 months.
Time frame: Week 48
Percentage of Participants Achieving Disease Activity Score (DAS28) Remission
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
Time frame: Weeks 24 and 48
Change in DAS28 From Baseline
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10.
Time frame: Weeks 24 and 48
Percentage of Participants With EULAR Response Rates of Good/ Moderate
The EULAR response rate was based on the assessment of disease activity using the DAS28. The EULAR response criteria included not only change in disease activity but current disease activity. To be classified as responders, participants had to have a significant change in DAS28 and a low current disease activity. There were 4 categories of EULAR response rates: good, moderate, good/moderate, and none.
Time frame: Weeks 24 and 48
Percentage of Participants Achieving an ACR50 Response
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: physician's global assessment of disease activity (MDG), patient's global assessment of disease activity (PGA), patient's assessment of pain, Health Assessment Questionnaire with Disability Index (HAQ-DI), and C-Reactive Protein (CRP).
Time frame: Weeks 24 and 48
Percentage of Participants Achieving an ACR70 Response
ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: physician's global assessment of disease activity (MDG), patient's global assessment of disease activity (PGA), patient's assessment of pain, HAQ-DI and CRP.
Time frame: Weeks 24 and 48
Percentage of Participants With a Reduction in the HAQ-DI Score
Health Assessment Questionnaire - Disability Index (HAQ-DI): The Stanford Health Assessment Questionnaire disability index is a patient reported questionnaire specific for RA. It consists of 20 questions referring to eight component. Reduction in the HAQ-DI score of 0.25 units from baseline to weeks 24 and 48 represented a minimal clinically relevant improvement.
Time frame: Weeks 24 and 48
Participants were recruited across 25 countries.
| Milestone | Placebo x 2 IV + Non-Biologic DMARD | Ocrelizumab 200 mg x 2 + Non-Biologic DMARD | Ocrelizumab 500 mg x 2 + Non-Biologic DMARD | Ocrelizumab 500 mg x 2 IV + Non-biologic DMARD (OLE) |
|---|---|---|---|---|
| Started | 277 | 277 | 282 | 0 |
| Completed | 205 | 222 | 237 | 0 |
| Not completed | 72 | 55 | 45 | 0 |
| Withdrew: Withdrawal by subject | 12 | 7 | 7 | 0 |
| Withdrew: Protocol violation | 1 | 3 | 0 | 0 |
| Withdrew: Early termination of the study | 24 | 20 | 21 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 4 | 3 | 0 |
| Withdrew: Lack of efficacy | 22 | 5 | 6 | 0 |
| Withdrew: Death | 2 | 1 | 1 | 0 |
| Withdrew: Adverse event | 11 | 13 | 7 | 0 |
| Milestone | Placebo x 2 IV + Non-Biologic DMARD | Ocrelizumab 200 mg x 2 + Non-Biologic DMARD | Ocrelizumab 500 mg x 2 + Non-Biologic DMARD | Ocrelizumab 500 mg x 2 IV + Non-biologic DMARD (OLE) |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 664 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 664 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 50 |
| Withdrew: Adverse event | 0 | 0 | 0 | 8 |
| Withdrew: Death | 0 | 0 | 0 | 7 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 13 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 4 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 0 | 4 |
| Withdrew: Early termination of the study | 0 | 0 | 0 | 578 |
ACR20 response: greater than or equal to (≥) 20% improvement in tender or swollen joint counts and 20% improvement in 3 of the following 5 criteria: 1) Physician's global assessment of disease activity, 2) participant assessment of disease activity, 3) Patient Assessment of Pain (visual analog scale \[VAS\]), 4) participant assessment of functional disability via a Health Assessment Questionnaire (HAQ), and 5) erythrocyte sedimentation rate (ESR) at each visit.
| Percentage | Placebo x 2 IV + Non-Biologic DMARD | Ocrelizumab 200 mg x 2 + Non-Biologic DMARD | Ocrelizumab 500 mg x 2 + Non-Biologic DMARD |
|---|---|---|---|
| Percentage of Responders at Week 24 | 22 (17.1 to 26.9) | 42.2 (36.4 to 48.1) | 47.9 (42.0 to 53.7) |
| Percentage of Responders at Week 48 | 19.5 (14.8 to 24.2) | 48.7 (42.9 to 54.6) | 50.7 (44.9 to 56.5) |
Major clinical response was defined as achieving an ACR70 response and maintaining this response for a consecutive period of at least 6 months.
| Percentage | Placebo x 2 IV + Non-Biologic DMARD | Ocrelizumab 200 mg x 2 + Non-Biologic DMARD | Ocrelizumab 500 mg x 2 + Non-Biologic DMARD |
|---|---|---|---|
| Percentage of Participants With a Major Clinical Response | 1.8 (0.2 to 3.4) | 4.0 (1.7 to 6.3) | 5.7 (3.0 to 8.4) |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
| Percentage | Placebo x 2 IV + Non-Biologic DMARD | Ocrelizumab 200 mg x 2 + Non-Biologic DMARD | Ocrelizumab 500 mg x 2 + Non-Biologic DMARD |
|---|---|---|---|
| Percentage of Participants at Week 24 | 1.8 (0.2 to 3.4) | 5.8 (3.0 to 8.5) | 6.0 (3.3 to 8.8) |
| Percentage of Participants at Week 48 | 1.4 (0.0 to 2.8) | 11.9 (8.1 to 15.7) | 12.1 (8.3 to 15.9) |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10.
| Score on a scale | Placebo x 2 IV + Non-Biologic DMARD | Ocrelizumab 200 mg x 2 + Non-Biologic DMARD | Ocrelizumab 500 mg x 2 + Non-Biologic DMARD |
|---|---|---|---|
| Baseline | 6.50 ± 1.014 | 6.47 ± 1.217 | 6.44 ± 1.039 |
| Week 24 | -0.99 ± 1.166 | -1.60 ± 1.307 | -1.91 ± 1.349 |
| Week 48 | -1.13 ± 1.404 | -2.11 ± 1.348 | -2.38 ± 1.496 |
The EULAR response rate was based on the assessment of disease activity using the DAS28. The EULAR response criteria included not only change in disease activity but current disease activity. To be classified as responders, participants had to have a significant change in DAS28 and a low current disease activity. There were 4 categories of EULAR response rates: good, moderate, good/moderate, and none.
| Percentage | Placebo x 2 IV + Non-Biologic DMARD | Ocrelizumab 200 mg x 2 + Non-Biologic DMARD | Ocrelizumab 500 mg x 2 + Non-Biologic DMARD |
|---|---|---|---|
| Week 24 | 31.4 | 54.2 | 61.0 |
| Week 48 | 24.9 | 58.8 | 60.3 |
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: physician's global assessment of disease activity (MDG), patient's global assessment of disease activity (PGA), patient's assessment of pain, Health Assessment Questionnaire with Disability Index (HAQ-DI), and C-Reactive Protein (CRP).
| Percentage | Placebo x 2 IV + Non-Biologic DMARD | Ocrelizumab 200 mg x 2 + Non-Biologic DMARD | Ocrelizumab 500 mg x 2 + Non-Biologic DMARD |
|---|---|---|---|
| Percentage of Participants at Week 24 | 7.9 (4.8 to 11.1) | 21.3 (16.5 to 26.1) | 24.8 (19.8 to 29.9) |
| Percentage of Participants at Week 48 | 9 (5.7 to 12.4) | 28.5 (23.2 to 33.8) | 30.9 (25.5 to 36.2) |
ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: physician's global assessment of disease activity (MDG), patient's global assessment of disease activity (PGA), patient's assessment of pain, HAQ-DI and CRP.
| Percentage | Placebo x 2 IV + Non-Biologic DMARD | Ocrelizumab 200 mg x 2 + Non-Biologic DMARD | Ocrelizumab 500 mg x 2 + Non-Biologic DMARD |
|---|---|---|---|
| Percentage of Participants at Week 24 | 2.9 (0.9 to 4.9) | 7.6 (4.5 to 10.7) | 9.9 (6.4 to 13.4) |
| Percentage of Participants at Week 48 | 4.3 (1.9 to 6.7) | 11.2 (7.5 to 14.9) | 18.1 (13.6 to 22.6) |
Health Assessment Questionnaire - Disability Index (HAQ-DI): The Stanford Health Assessment Questionnaire disability index is a patient reported questionnaire specific for RA. It consists of 20 questions referring to eight component. Reduction in the HAQ-DI score of 0.25 units from baseline to weeks 24 and 48 represented a minimal clinically relevant improvement.
| Percentage | Placebo x 2 IV + Non-Biologic DMARD | Ocrelizumab 200 mg x 2 + Non-Biologic DMARD | Ocrelizumab 500 mg x 2 + Non-Biologic DMARD |
|---|---|---|---|
| Percentage of Participants at Week 24 | 32.9 (27.3 to 38.4) | 52.3 (46.5 to 58.2) | 58.5 (52.8 to 64.3) |
| Percentage of Participants at Week 48 | 23.1 (18.1 to 28.1) | 50.5 (44.7 to 56.4) | 51.8 (45.9 to 57.6) |
Collected over From Day 1 to Week 48 and Week 96. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo x 2 IV + Non-Biologic DMARD | 5/276 (1.8%) | 41/276 (14.9%) | 152/276 (55.1%) |
| Ocrelizumab 200 mg x 2 + Non-Biologic DMARD | 2/276 (0.7%) | 46/276 (16.7%) | 153/276 (55.4%) |
| Ocrelizumab 500 mg x 2 + Non-Biologic DMARD | 4/284 (1.4%) | 40/284 (14.1%) | 158/284 (55.6%) |
| Ocrelizumab 500 mg x 2 IV + Non-biologic DMARD (OLE) | 11/664 (1.7%) | 138/664 (20.8%) | 361/664 (54.4%) |
| Event | Placebo x 2 IV + Non-Biologic DMARD | Ocrelizumab 200 mg x 2 + Non-Biologic DMARD | Ocrelizumab 500 mg x 2 + Non-Biologic DMARD | Ocrelizumab 500 mg x 2 IV + Non-biologic DMARD (OLE) |
|---|---|---|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 7/276 | 4/276 | 4/284 | 7/664 |
| PneumoniaInfections and infestations | 5/276 | 5/276 | 1/284 | 11/664 |
| CellulitisInfections and infestations | 3/276 | 0/276 | 0/284 | 1/664 |
| Myocardial infarctionCardiac disorders | 1/276 | 2/276 | 1/284 | 6/664 |
| AnaemiaBlood and lymphatic system disorders | 2/276 | 0/276 | 0/284 | 1/664 |
| Angina pectorisCardiac disorders | 1/276 | 2/276 | 1/284 | 1/664 |
| BronchitisInfections and infestations | 2/276 | 0/276 | 0/284 | 1/664 |
| Pulmonary tuberculosisInfections and infestations | 0/276 | 2/276 | 0/284 | 0/664 |
| Tendon ruptureInjury, poisoning and procedural complications | 2/276 | 0/276 | 1/284 | 1/664 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/276 | 2/276 | 1/284 | 2/664 |
| Event | Placebo x 2 IV + Non-Biologic DMARD | Ocrelizumab 200 mg x 2 + Non-Biologic DMARD | Ocrelizumab 500 mg x 2 + Non-Biologic DMARD | Ocrelizumab 500 mg x 2 IV + Non-biologic DMARD (OLE) |
|---|---|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 25/276 | 41/276 | 41/284 | 128/664 |
| Upper respiratory tract infectionInfections and infestations | 36/276 | 37/276 | 45/284 | 96/664 |
| Urinary tract infectionInfections and infestations | 23/276 | 19/276 | 24/284 | 78/664 |
| NasopharyngitisInfections and infestations | 31/276 | 28/276 | 22/284 | 69/664 |
| BronchitisInfections and infestations | 19/276 | 28/276 | 22/284 | 64/664 |
| SinusitisInfections and infestations | 14/276 | 13/276 | 13/284 | 53/664 |
| HypertensionVascular disorders | 21/276 | 18/276 | 19/284 | 44/664 |
| InsomniaPsychiatric disorders | 12/276 | 9/276 | 16/284 | 0/664 |
| DarrhoeaGastrointestinal disorders | 10/276 | 15/276 | 15/284 | 0/664 |
| NauseaGastrointestinal disorders | 15/276 | 11/276 | 10/284 | 0/664 |
Intent-toTreat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis
| Age, Continuous(years) | Placebo x 2 IV + Non-Biologic DMARD | Ocrelizumab 200 mg x 2 + Non-Biologic DMARD | Ocrelizumab 500 mg x 2 + Non-Biologic DMARD | Total |
|---|---|---|---|---|
| Mean | 54.1 ± 11.3 | 54.5 ± 11.2 | 53.8 ± 11.6 | 54.2 ± 11.3 |
| Sex: Female, Male(Participants) | Placebo x 2 IV + Non-Biologic DMARD | Ocrelizumab 200 mg x 2 + Non-Biologic DMARD | Ocrelizumab 500 mg x 2 + Non-Biologic DMARD | Total |
|---|---|---|---|---|
| Female | 215 | 214 | 236 | 665 |
| Male | 62 | 63 | 46 | 171 |
| Race/Ethnicity, Customized(Participants) | Placebo x 2 IV + Non-Biologic DMARD | Ocrelizumab 200 mg x 2 + Non-Biologic DMARD | Ocrelizumab 500 mg x 2 + Non-Biologic DMARD | Total |
|---|---|---|---|---|
| American indian or Alaska native | 9 | 8 | 9 | 26 |
| Asian (Indian Subcontinent) | 1 | 0 | 0 | 1 |
| Asian (Other than Indian subcontinent) | 39 | 38 | 38 | 115 |
| Black | 16 | 18 | 12 | 46 |
| Native Hawaiian or other Pacific Islander | 0 | 1 | 2 | 3 |
| Other | 6 | 11 | 14 | 31 |
| White | 206 | 201 | 207 | 614 |
Showing the first 100 of 266 sites across 25 countries. Choose a country and city above to see the rest.
Ran from May 2007 to primary completion in Jan 2010, 32 months.
Results were first posted in Aug 2019, 9 years 6 months after primary completion. A results delay was requested in Aug 2013.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocrelizumab